Australian recommendations for the management of drug-resistant tuberculosis, 2023

Recent updates in international guidance on the treatment of drug-resistant tuberculosis (DR-TB) in both adults and children reflect significant advances in laboratory diagnostics, strengthened evidence for newer all oral treatment options and an emphasis on patient-centred care and support.[4][9][10][11] The implementation of these newer regimens should be subject to expert oversight at the case management level, careful patient selection, a strong emphasis on monitoring for adverse drug effects and close involvement of the patient in the decision-making process.It is important to acknowledge that this is a rapidly evolving area with further changes to treatment options anticipated in the next few years.